Apart from the RET proto-oncogene (RET) no other genes have been found to be involved in
medullary thyroid carcinoma (MTC) tumorigenesis. Germline RET mutations are seen …

Context Recent data on long-term outcomes and aggressiveness of medullary thyroid
carcinoma (MTC) are lacking for patients with multiple endocrine neoplasia type 2 (MEN2) …

Background Since DNA tests have enabled reliable identification of asymptomatic RET
(rearranged during transfection) gene carriers, myriads of publications have appeared on …

Two kindreds with familial medullary thyroid carcinoma (MTC) are described in which
affected family members had variable clinical and pathologic manifestations. Genetic testing …

Medullary thyroid cancer (MTC) is an aggressive form of thyroid cancer that occurs in both
heritable and sporadic forms. Discovery that mutations in the rearranged during transfection …

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor that represents< 5% of all
thyroid malignancies and is generally more aggressive than differentiated thyroid cancer …

Purpose: Prophylactic thyroidectomy has been encouraged for children with REarranged
during Transfection (RET) germline mutations to prevent the onset, persistence, or …

Background: Medullary thyroid carcinoma (MTC) comprises 1–2% of all thyroid cancers, yet
15% of all thyroid cancer-related deaths. While up to 20% of cases may be predicted due to …

Background: Nonmedullary thyroid cancers (NMTC) originate from the follicular cells of the
thyroid gland and account for over 90% of all thyroid cancers. About 3–10% of the NMTCs …

Medullary thyroid cancer: therapeutic targets and molecular... : Current Opinion in Oncology
Medullary thyroid cancer: therapeutic targets and molecular markers : Current Opinion in …